Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
NOTE: If you attended the live CE activity titled "Update on Sterile Compounding in Health Systems: Opportunities and Challenges" that was held on June 6, 2017 (on-site in Minneapolis, Minnesota or via the concurrent webinar), AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-0000-17-140-L03-P), you are NOT eligible to also receive CE credit for this home-study activity.
The regulations for sterile IV compounding continue to be updated and revised. The pharmacy department leadership, along with their staff, are responsible for ensuring compliance with these standards to protect patients and provide quality care. Staying up-to-date with these standards can be challenging and time consuming. State and federal agencies along with accreditation services are now monitoring for full compliance with these regulations during inspections. This educational session will review the revised and new USP Chapter <797> and <800> standards to help ensure compliance. The importance of batch testing and an overview of how that is accomplished will also be reviewed. Pharmacy department leadership strategies to maintain compliance with the standards will also be discussed. The activity will conclude with a panel discussion to address audience questions.
The target audience for this activity includes pharmacy administrators, compounding pharmacists, and pharmacists in health-system settings. At the completion of this symposium, the participant will be able to:
Louis S. Diorio, RPh, FAPhA
LDT Health Solutions, Inc.
Wayne, New Jersey
Fred Massoomi, Pharm.D., FASHP
Senior Director of Health-system & Hospital Services
Susan J. Schniepp
Regulatory Compliance Associates, Inc.
Albuquerque, New Mexico
Release Date: 6-6-2017
Expiration Date: 7-31-2018
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-17-140-H03-P has been assigned to this home-study knowledge-based activity (initial release date 6-6-17). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Mr. Diorio is
an employee and shareholder of LDT Health Solutions, Inc. and has served as a speaker
for Grifols USA and Spectrum Pharmacy Products. Dr. Massoomi is an employee - consultant
for Visante, Inc. and has served as a speaker for Baxter, Equashield, Hospira, and
ICU Medical, and as a writer for BD. Ms. Schniepp has served as a consultant for Regulatory
Compliance Associates, as an auditor for NSF, and as a consultant for PharMEDium Services,
LLC. Content review and conflict resolution conducted by James Dorociak, PharmD, MSc.
Dr. Dorociak has no relevant financial relationships to disclose. A portion of grant
funds received by ProCE from PharMEDium Services, LLC will be used to compensate the
faculty for this presentation.
Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This CE activity is supported by an educational grant from PharMEDium Services, LLC.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.